Ofatumumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1008 publications

Pregnancy Exposure to Anti-CD20 Monoclonal Antibodies in Patients With Multiple Sclerosis: Results From an Italian Multicenter Registry Study.

Pregnancy Exposure to Anti-CD20 Monoclonal Antibodies in Patients With Multiple Sclerosis: Results From an Italian Multicenter Registry Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 28, 2026

B-cell repopulation and postpartum MS disease activity following ofatumumab cessation for pregnancy in women with multiple sclerosis.

B-cell repopulation and postpartum MS disease activity following ofatumumab cessation for pregnancy in women with multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 23, 2026

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal: Journal of medical economics

Published: June 24, 2026

Letter to the editor regarding "Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice".

Letter to the editor regarding "Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice".

Journal: Neurodegenerative disease management

Published: May 24, 2026

Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis.

Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: May 22, 2026

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies.

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 12, 2026

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Journal: Neurology. Clinical practice

Published: May 11, 2026

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Journal: Drugs - real world outcomes

Published: May 07, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 28, 2026

Individualized repetitive intravenous immunoglobulin therapy for a 79-year-old patient with GlyR antibody-positive PERM: a case report and literature review.

Individualized repetitive intravenous immunoglobulin therapy for a 79-year-old patient with GlyR antibody-positive PERM: a case report and literature review.

Journal: Frontiers in immunology

Published: April 28, 2026

Eculizumab treatment in the salvage therapy of MOGAD: a case report.

Eculizumab treatment in the salvage therapy of MOGAD: a case report.

Journal: Frontiers in immunology

Published: April 21, 2026

Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies.

Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies.

Journal: Drugs - real world outcomes

Published: April 06, 2026

Showing 1-12 of 1,008

Last Updated: 09/26/2026